Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Publication year range
1.
Neural Plast ; 2015: 186385, 2015.
Article in English | MEDLINE | ID: mdl-26550496

ABSTRACT

Schwann cell (SC) transplantation exhibits significant potential for spinal cord injury (SCI) repair and its use as a therapeutic modality has now progressed to clinical trials for subacute and chronic human SCI. Although SC implants provide a receptive environment for axonal regrowth and support functional recovery in a number of experimental SCI models, axonal regeneration is largely limited to local systems and the behavioral improvements are modest without additional combinatory approaches. In the current study we investigated whether the concurrent delivery of the polyamine putrescine, started either 30 min or 1 week after SCI, could enhance the efficacy of SCs when implanted subacutely (1 week after injury) into the contused rat spinal cord. Polyamines are ubiquitous organic cations that play an important role in the regulation of the cell cycle, cell division, cytoskeletal organization, and cell differentiation. We show that the combination of putrescine with SCs provides a significant increase in implant size, an enhancement in axonal (sensory and serotonergic) sparing and/or growth, and improved open field locomotion after SCI, as compared to SC implantation alone. These findings demonstrate that polyamine supplementation can augment the effectiveness of SCs when used as a therapeutic approach for subacute SCI repair.


Subject(s)
Axons/drug effects , Putrescine/therapeutic use , Schwann Cells/transplantation , Sensory Receptor Cells/drug effects , Serotonin/physiology , Spinal Cord Injuries/therapy , Animals , Combined Modality Therapy , Contusions/pathology , Female , Infusions, Subcutaneous , Locomotion , Nerve Regeneration , Putrescine/administration & dosage , Rats , Rats, Inbred F344 , Receptors, Calcitonin Gene-Related Peptide/metabolism , Recovery of Function , Spinal Cord Injuries/drug therapy
2.
J Neurotrauma ; 29(12): 2244-9, 2012 Aug 10.
Article in English | MEDLINE | ID: mdl-22708918

ABSTRACT

Inducible nitric oxide synthase (iNOS) is a key mediator of inflammation and oxidative stress produced during pathological conditions, including neurodegenerative diseases and central nervous system (CNS) injury. iNOS is responsible for the formation of high levels of nitric oxide (NO). The production of highly reactive and cytotoxic NO species, such as peroxynitrite, plays an important role in secondary tissue damage. We have previously demonstrated that acute administration of iNOS antisense oligonucleotides (ASOs) 3 h after moderate contusive spinal cord injury (SCI) potently inhibits iNOS-mediated increases in NO levels, leading to reduced blood-spinal cord barrier permeability, decreased neutrophil accumulation, and less neuronal cell death. In the current study we investigated if iNOS ASOs could also provide long-term (10-week) histological and behavioral improvements after moderate thoracic T8 contusive SCI. Adult rats were randomly assigned to three groups (n=10/group): SCI alone, SCI and mixed base control oligonucleotides (MBOs), or SCI and iNOS ASOs (200 nM). Oligonucleotides were administered by spinal superfusion 3 h after injury. Behavioral analysis (Basso-Beattie-Bresnahan [BBB] score and subscore) was employed weekly for 10 weeks post-SCI. Although animals treated with iNOS ASOs demonstrated no significant differences in BBB scores compared to controls, subscore analysis revealed a significant improvement in foot positioning, trunk stability, and tail clearance. Histologically, while no gross improvement in preserved white and gray matter was observed, greater numbers of surviving neurons were present adjacent to the lesion site in iNOS ASO-treated animals than controls. These results support the effectiveness of targeting iNOS acutely as a therapeutic approach after SCI.


Subject(s)
Neurons/enzymology , Nitric Oxide Synthase Type II/antagonists & inhibitors , Nitric Oxide Synthase Type II/genetics , Oligonucleotides, Antisense/pharmacology , Recovery of Function/genetics , Spinal Cord Injuries/enzymology , Spinal Cord Injuries/therapy , Amidines/pharmacology , Amidines/therapeutic use , Animals , Benzylamines/pharmacology , Benzylamines/therapeutic use , Blood-Brain Barrier , Contusions/enzymology , Contusions/therapy , Enzyme Inhibitors/pharmacology , Female , Guanidines/pharmacology , Guanidines/therapeutic use , Locomotion/physiology , Rats , Rats, Inbred F344
SELECTION OF CITATIONS
SEARCH DETAIL